Wer hat mehr Informationen zu Arpida? - 500 Beiträge pro Seite

[nazim4]

Wer kann Arpida empfehlen oder weiß näheres? Würdet ihr Arpida kaufen?

[battleisle2003]

Bin schon seit 11,44 bei Arpida mit einer kleinen Position dabei und bis jetzt sehr zufrieden mit der Entwicklung. Schade ist nur der relativ schwache Umsatz in Deutschland. Dies hat sich aber seit einiger Empfehlungen, z.B von Börse Online und Der Aktionär schon leicht gebessert. Infos gibt es z.B bei www.arpida.ch oder www.deraktionaer.de.
Ich glaube, daß die Aktie auch jetzt noch kaufenswert ist und aufgrund des Potentials von iclaprim weitere Kurschancen enthält (Marktanteil für Mittel gegen bakterielle Infektionen während eines Krankenaufenthalt ca. 8 Mrd. Dollar). Hier werden wir bei Zulassung von iclaprim sicher noch viel Spaß haben....

[lottojan10]

hier ein par infos



Overview
Arpida was founded in 1997 by Dr Dieter Gillessen, Prof. Bernhard Erni and Dr Ivan Kompis along with Dr André Lamotte from New Medical Technologies (NMT, now HBM BioVentures). Arpida’s mission is to discover and develop innovative drugs and provide caregivers with novel therapies to overcome the “antibiotic crisis”. Arpida has a fully integrated platform for the discovery and development of drug candidates that seek to address the increasing prevalence of resistance in Gram-positive and Gram-negative bacteria.

Arpida’s leading product candidate, injectable iclaprim, is a bactericidal broad-spectrum antibiotic that targets severe bacterial infections requiring hospital treatment and which are resistant to most current therapies. In 2005, Arpida began a global Phase III programme with injectable iclaprim for the treatment of hospitalised patients with complicated skin and skin structure infections (cSSSI), such as infected burns, ulcers and surgical wounds. The Phase III programme, which has been granted US fast track status, consists of two independent trials in North America, Europe and Rest of World and will compare iclaprim with linezolid (marketed as Zyvox®). These Phase III trials are on-going and patient recruitment is progressing as anticipated.

An oral formulation of iclaprim is in Phase I clinical trials under approved protocols from US and European Health Authorities. Oral iclaprim could offer the possibility of switching patients from intravenous antibiotic therapy to allow earlier hospital discharge. This is potentially a very important benefit as such a switch will not only reduce healthcare costs but could significantly reduce the probability of patients contracting new infections.

In June 2005 the Company announced it has successfully completed an innovative Phase I clinical study, known as a Bronchial Alveolar Lavage study, demonstrating that iclaprim achieves high concentrations in specific lung compartments in healthy volunteers. These results pave the way for a new clinical development programme with iclaprim for the treatment of pneumonia.

Arpida’s third most advanced programme, AR-709, is a broad spectrum and bactericidal antibiotic that targets upper and lower respiratory tract infections in the community setting. AR-709 is in late pre-clinical development.

In addition, the company has a further 12 pre-clinical antibiotic programmes derived from its own discovery platform, which are at various stages of pre-clinical development.

Arpida is based near Basel, Switzerland, with additional facilities in Denmark. The company currently has 77 employees.



Corporate Strategy
Arpida’s goal is to become a world-leading biopharmaceutical company in the area of antibacterial drugs. In the short term Arpida focuses on developing its existing product portfolio, mainly injectable iclaprim, oral iclaprim and AR-709.

The company’s longer term strategy is to advance promising candidates from its in-house research programmes into clinical development to support future growth. Arpida will also seek attractive co-development opportunities at various stages of the discovery and development process within the anti-infectives sector. At the appropriate time, Arpida aims to establish its own specialist sales and marketing infrastructure to complement its integrated research and development capabilities.







© 2005 | [e-mail]


lotto

[lottojan10]

Antwort auf Beitrag Nr.: 20.432.600 von nazim4 am 28.02.06 21:09:58

noch mehr infos:


March 21st, 2006
Independent data review supports continuation of Phase III programme with intravenous iclaprim

Download press release (pdf) English German French


March 2nd, 2006
Arpida announces full year 2005 financial results

Download press release (pdf) English German French


February 13th, 2006
Arpida presents additional clinical evidence of good bioavailability of oral iclaprim

Download press release (pdf) English


January 25th 2006
Arpida confirms good bioavailability of iclaprim from an oral formulation

Download press release (pdf) English

January 11th 2006
Arpida updates scientific community on progress of iclaprim

Download press release (pdf) English


October 17th 2005
Arpida announces positive in vitro results on AR-709

Download press release (pdf) English


August 23th 2005
Arpida receives FDA Fast Track Designation for Intravenous iclaprim

Download press release (pdf) English / French / German


August 16th 2005
Arpida Interim Results for six Months ended 30th June 2005

Download press release (pdf) English / French / German


July 13th 2005
Arpida Granted IND For Oral Iclaprim from US FDA

Download press release (pdf) English


June 22nd 2005
Arpida Announces Positive Results from a Clinical Trial to Determine Iclaprim Levels in Lungs of Human Volunteers

Download press release (pdf) English


May 4th 2005
Arpida successfully completes Initial Public Offering

Download press release (pdf) English / German / French


April 15th 2005
Arpida appoints leading anti-infectives expert to
Scientific Advisory Board

Download press release (pdf) English


April 11th 2005
Arpida plans initial public offering on the SWX Swiss Exchange.

Download press release (pdf) English / German / French


March 16th 2005
Arpida ready to commence global Phase III clinical trial programme for iclaprim. FDA clearance paves way for Phase III trials of new broad-spectrum antibiotic in the US.

Download press release (pdf) English / German / French











© 2005 | [e-mail]



lotto

[lottojan10]

Antwort auf Beitrag Nr.: 20.630.907 von battleisle2003 am 11.03.06 15:22:11

und noch mehr:

Bacteria have increasingly become resistant to many, if not all, currently available antibiotics. In the hospital environment drug resistance has become a major cause of morbidity, mortality and increased healthcare costs. It has been shown for example that around 70% of patients who acquire an infection in a US hospital have infections resistant to at least one antibiotic. Nearly US$5 billion are added to US health care costs every year as a result of infections that patients contract while hospitalised for other health problems.

Bacterial resistance has also been increasing in the community. In particular, Streptococcus pneumoniae, a major cause of respiratory tract infections (RTI) as well as inner ear infections (otitis media), has become resistant to multiple drugs. Since the first reports of Streptococcus pneumoniae resistance to penicillin in 1967, multiple antibiotic resistance has rapidly increased world-wide reaching peaks of 30% in some communities in the US and 80% in some regions of some other countries in 1998.

The total world-wide market for anti-infectives exceeded US$45 billion in 2004. US$26 billion were spent on antibacterials, about 70% in the community and 30% for hospital antibiotics.



For further information on antibiotic resistance, please visit:

CDC’s National Center for Infectious Diseases (NCID)
www.cdc.gov/drugresistance/
www.cdc.gov/ncidod/emergplan/antiresist/page_2.htm
www.cdc.gov/ncidod/hip/ARESIST/aresist.htm

National Institute of Allergy and Infectious Diseases
www.niaid.nih.gov/factsheets/antimicro.htm

FDA
www.fda.gov/oc/opacom/hottopics/anti_resist.html
www.fda.gov/fdac/features/2002/402_bugs.html





© 2005 | [e-mail]




lotto

[nazim4]

Antwort auf Beitrag Nr.: 20.974.840 von lottojan10 am 28.03.06 15:13:26

´Hallo Lottojan 10,

weißt du denn auch, warum Arpida jetzt so stark gefallen ist? Man muß wohl in der Schweiz nach forschen.
Ich hatte leider immer an Arpida gezweifelt, weil ich es nicht verstehen kann, wie man eine ganze Firma nur auf einem Medikament aufbauen kann. Außerdem habe ich mitbekommen, das Iclaprim schon in der geringsten Dosis starke Nebenwirkungen hervorruft. Aber ich habe es so verstanden, das Iclaprim trotzdem auf jeden Fall auf den Markt kommt, da es bis jetzt das einzigste Mittel ist, welches gegen die gefürchteten Krankenhausbakterien, die speziell zur Lungenentzündung führen, wirkt. Der Patient kann sich also entscheiden, halb tod oder ganz tod, wie bei der Chemotherapie.

[igla]

http://www.vermoegensaufbau-fonds.de/upload/WW_0306_screen_1…

Seite 23